This move is archived. Current quotes and coverage live on the stock page.
Follow EPRX
Eupraxia Pharmaceuticals Inc is seeing a significant rise in its stock price, which reflects positive sentiment from investors.
Eupraxia Pharmaceuticals Inc (EPRX.TO) gained 2.97% today, closing at CA$9.36. This increase suggests that investors are responding favorably, possibly due to recent improvements in the company's financial health and market position.
Investor takeaway: Keep an eye on Eupraxia's developments, especially regarding its public offerings and clinical milestones, as these could significantly impact stock performance.
Advertisement
Eupraxia Pharmaceuticals Inc
EPRX.TO
EPRX.TO
Eupraxia Pharmaceuticals Inc
WealthAwesomeMarket cap
$783.63M
52W high
$13.08
52W low
$7.35
1W change
+13.45%
Beta
1.49
Analyst Price Targets
Based on analyst covering EPRX · as of Sep 28, 2026
Wall Street analysts forecast EPRX stock price to rise 25.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$16.33
+25.7% Upside
Previously C$16.00 on Sep 17, 2026
Current Price
C$12.99
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on EPRX's historical volatility
30-Day Vol
80.6%
Annualized
90-Day Vol
63.4%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$15.53
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$13.79 | C$10.44 – C$18.20 |
| 60 trading days | C$14.63 | C$9.88 – C$21.68 |
| 90 trading days | C$15.53 | C$9.60 – C$25.13 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Eupraxia Pharmaceuticals Inc's stock rises 2.97%
The company's market capitalization is now around CA$610.8 million, highlighting its growing presence in the biopharmaceutical sector.
Bull case
Recent public offerings have strengthened Eupraxia's cash reserves, giving the company the financial flexibility to push forward with its clinical programs. This could boost investor confidence moving forward.
Bear case
Even with today’s gains, the lack of consistent profitability and the absence of dividends might make some risk-averse investors hesitant, especially in a volatile market.
Advertisement
Recent Developments Boost Investor Confidence
Eupraxia's stock price increase aligns with its recent financial activities, including successful public offerings that have raised significant capital. The company announced a public offering of common shares, which likely reassured investors about its financial stability and growth potential.
Market Reaction and Future Outlook
Today's positive market reaction reflects broader confidence in Eupraxia's strategic direction. As the company continues to advance its clinical programs, particularly in treating Eosinophilic Esophagitis, investors are optimistic about future developments and potential profitability.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
